Literature DB >> 10926788

Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.

M Furuya1, H Ishikura, Y Kawarada, Y Ogawa, N Sakuragi, S Fujimoto, T Yoshiki.   

Abstract

OBJECTIVES AND METHODS: The growth of an ovarian cystic neoplasm often involves its invasion into and destruction of the extracellular matrix. We examined neoplastic cysts of ovarian mucinous tumors for the presence of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) using zymography (in situ zymography, gelatin zymography, and casein zymography) and enzyme-linked immunosorbent assay.
RESULTS: Matriolytic activity was detected within the cystic contents and cytoplasm of the lining epithelial cells of the cyst by in situ zymography. This intracystic matriolytic activity was thought to originate mainly in the epithelial cells. The activated form of MMP-9 was seen in all carcinoma and borderline fluids and in 7 of 15 adenomas. The concentration of MMP-9 was higher in carcinoma fluids than in borderline and adenoma fluids (P < 0.05). TIMP-1, which specifically binds to MMP-9, was also higher in carcinoma and borderline fluids than in adenoma fluids (P < 0.05). MMP-2 activity was nearly ubiquitously present in all cyst fluids, irrespective of the fluid's histologic category. The amount of MMP-2 was highest in the carcinoma category, although not to a statistically significant degree. TIMP-2, a specific inhibitor for MMP-2, was significantly lower in the borderline category than in the adenoma category. The molar ratios of TIMP-1/MMP-9 (not significant) and TIMP-2/MMP-2 (P < 0.05) were higher in the adenoma category. Expressions of trypsin, MMP-7, and MMP-9 were generally higher in carcinoma and borderline fluids than in adenoma fluids.
CONCLUSIONS: These observations indicate the importance of ovarian cystic fluids for analyzing tumor-associated matriolytic activities. The findings suggest that these matriolytic enzymes, together with the presence of their inhibitors, play an important role in the growth of ovarian mucinous tumors. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926788     DOI: 10.1006/gyno.2000.5856

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients.

Authors:  Agnieszka Hałoń; Ewa Nowak-Markwitz; Piotr Donizy; Rafal Matkowski; Adam Maciejczyk; Tserenchunt Gansukh; Balázs Györffy; Marek Spaczyński; Maciej Zabel; Hermann Lage; Pawel Surowiak
Journal:  J Histochem Cytochem       Date:  2012-04-17       Impact factor: 2.479

2.  Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model.

Authors:  Prakash Vempati; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

3.  The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation.

Authors:  A Paju; T Sorsa; T Tervahartiala; E Koivunen; C Haglund; A Leminen; T Wahlström; T Salo; U H Stenman
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

Review 4.  Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer.

Authors:  Y Zhang; Q Chen
Journal:  Braz J Med Biol Res       Date:  2017-05-18       Impact factor: 2.590

Review 5.  The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.

Authors:  Ruth M Escalona; Emily Chan; George Kannourakis; Jock K Findlay; Nuzhat Ahmed
Journal:  Int J Mol Sci       Date:  2018-02-02       Impact factor: 5.923

6.  Ovarian cancer stroma: pathophysiology and the roles in cancer development.

Authors:  Mitsuko Furuya
Journal:  Cancers (Basel)       Date:  2012-07-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.